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The purpose of this volunteer study was to investigate
whether pretreatment with UDCA before the administration of
99mTc DISIDA affects the biliary excretion of the DISIDA, and
whether it can shorten the total imaging time. Ten young,
healthy volunteers (eight males, two females, mean age: 26.3
± 2.1 years) participated in the study. Hepatobiliary scinti-
graphies were performed twice per volunteer within three days,
for the control and the UDCA-pretreated studies. In the control
study, the gallbladder (GB) was observed first in four cases
and the intestine was observed first in another four cases; in
contrast, in the UDCA challenge study, the GB was observed
first in eight cases. The quantitative results for the factors
related to the GB differed significantly between the control
and challenge studies. When the subjects were pretreated with
UDCA, the time duration until visualization of the GB was
shortened, and the maximum activity of the GB became more
intense. In conclusion, UDCA pretreatment before hepato-
biliary scintigraphy can shorten the total imaging time for
evaluating functional obstructions of the cystic duct and
increase the specificity of the process.
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INTRODUCTION
Hepatobiliary scintigraphy has been used clin-
ically to diagnose acute cholecystitis. On a typical
normal scintigraphy performed with
99mTc 2,6-
diisopropyl iminodiacetic acid (DISIDA) agents,
the common bile duct (CBD) and gallbladder (GB)
are visualized 10-30 minutes after the intravenous
administration of this radiopharmaceutical agent.
However, the patients suspected of having acute
cholecystitis do not show any activity of the gal-
lbladder for up to four hours after the radiophar-
maceutical administration, or within 30 minutes
after the administration of morphine sulfate.
These findings are interpreted as being consistent
with a cystic duct obstruction, and thus suggest
acute cholecystitis. In spite of the high diagnostic
accuracy of hepatobiliary scintigraphy, with a
sensitivity of 97% and specificity of 90%, conven-
tional imaging protocols frequently require de-
layed imaging for up to four hours after injection.
1
Delayed imaging is logistically inconvenient, and
it may not be feasible in some clinical settings.
Pharmacological interventions, including mor-
phine augmentation and CCK pretreatment, have
been used in efforts to shorten the total imaging
time.
2,3 Unfortunately, these pharmaceutical
agents have not been widely used in the clinical
setting due to the problem of applicability to the
patients.
Ursodeoxycholic acid (UDCA) is the 7 beta-
epimer of chenodeoxycholic acid, and exerts mul-
tiple hepatoprotective activities. It modifies the
bile acid pool, decreasing the levels of the endo-
genous hydrophobic bile acids while increasing
the proportion of the nontoxic hydrophilic bile
acids. It also has a choleretic effect, increasing the
hepatocellular bile acid excretion, as well as
having cytoprotective, antiapoptotic, and immu-
nomodulatory properties.
4-6 In clinical practice,
UDCA has been used to improve cholestasis.
4,7
Pretreatment with Ursodeoxycholic Acid (UDCA) as a Novel
Pharmacological Intervention in Hepatobiliary Scintigraphy
Hwan-Jeong Jeong
1,2 and Chang-Guhn Kim
3
1Department of Nuclear Medicine, Chonbuk National University Medical School,
2Research Institute of Clinical Medicine,
Chonbuk National University Hospital, Jeonju, Korea;
3Department of Nuclear Medicine, Wonkwang University School of Medicine, Iksan, Jellabuk-do, Korea.
Received August 13, 2004
Accepted February 18, 2005
Reprint address: requests to Dr. Chang-Guhn Kim, Department
of Nuclear Medicine, Wonkwang University Hospital, 344-2
Sinyong-dong, Iksan, Jellabuk-do 570-711, Korea. Tel: 82-63-850-
1367, Fax: 82-63-852-1310, E-mail: leokim@wonkwang.ac.krUDCA Pretreatment in Hepatobiliary Scintigraphy
Yonsei Med J Vol. 46, No. 3, 2005
We thought these properties of UDCA could be
applied to DISIDA to cause the rapid excretion of
DISIDA into the hepatic duct and the fast filling
of the gallbladder with a greater amount of
DISIDA per unit time.
The aim of this study was to evaluate whether
pretreatment with UDCA prior to the adminis-
tration of
99mTc DISIDA affects the biliary ex-
cretion of the DISIDA, and whether it has the
possibility of shortening the total imaging time.
MATERIALS AND METHODS
Subjects
We studied 10 young, healthy volunteers (eight
males, two females, mean age: 26.3 ± 2.1 years).
All volunteers were studied after fasting over-
night for at least eight hours to prepare the
appropriate conditions for hepatobiliary scintig-
raphy. Hepatobiliary scintigraphies were per-
formed twice per volunteer within three days for
the control and the UDCA pretreatment studies.
Nobody complained of any side effects of the
UDCA pretreatment until one week after the
study. The ethics committee of the university hos-
pital approved the study, and informed consent
was obtained from each subject.
Scintigraphic test procedure
Hepatobiliary scintigraphy was evaluated after
the intravenous injection of 370 MBq of
99mTc
DISIDA. For the control study, the volunteers did
not receive any pretreatment except for the over-
night fast. For the UDCA pretreatment, they
orally ingested two 100 mg tablets of UDCA 15
minutes before the radiopharmaceutical injection.
A gamma camera (Millennium MG, GE, Mil-
waukee, Wisconsin, USA) equipped with a low-
energy, high-resolution, parallel hole collimator
and with a 20% window centered over the 140
KeV photopeak was used. The hepatobiliary scin-
tigraphy was performed for 60 minutes in a
dynamic mode (10 sec × 60 frames, 60 sec × 50
frames). The data were collected in a 128 × 128
matrix.
Data analysis
Two nuclear physicians observed the hepato-
biliary scintigraphies. The time points when the
gall bladder, common bile duct, and intestine
were visualized for the first time, the grading of
bowel activity, and the earliest organ visualized
between the GB and the intestine were decided by
consensus. The bowel activity in the scintigraphy
was subjectively divided into 0 (no activity), 1
(mild), 2 (moderate), and 3 (intense), and the
retained hepatic uptake ratio was calculated as the
total hepatic uptake excepting gall bladder in the
last image divided by the maximal total count of
images. This ratio was used to evaluate the de-
gree of excretory potential attributable to UDCA.
To correct the background activity, the region of
interest (ROI) was drawn in the heart. Using sub-
traction software, the corrected maximum ac-
tivities of the GB and the superior portion of the
right hepatic lobe for one hour were calculated.
All data were expressed as mean ± SD. A
paired t-test was used for the comparison of the
two studies for each volunteer. A p < 0.05 was con-
sidered statistically significant.
RESULTS
The results of the visual evaluation of the con-
trol and UDCA pretreatment hepatobiliary scintig-
raphies in the volunteers show the changes in the
scintigraphic patterns. In the control study, in two
cases the intestine was not observed, in four cases
the GB was observed first, and in the remaining
four cases, the GB was observed after the visuali-
zation of the intestine. In the UDCA challenge
study, the GB was observed first in eight cases. In
two cases, the GB was visualized later. Addi-
tionally, in the comparison of the time intervals,
in the cases when the intestine was visualized
first, the control studies took 10.3 ± 2.6 minutes,
but the UDCA pretreatment shortened the in-
tervals to 3.0 ± 1.4 minutes.
Fig. 1 is a case in which the GB was visualized
later than the intestine in the control study, but
was visualized first in the UDCA challenge study.
Fig. 2 shows the convergence of the observation
times of the GB in the eight cases where the GBHwan-Jeong Jeong and Chang-Guhn Kim
Yonsei Med J Vol. 46, No. 3, 2005
was observed first in the UDCA pretreatment
hepatobiliary scintigraphies.
Comparisons of the quantitative results for
several factors are shown in Table 1. Of all the
factors, the factors related to the GB differed sig-
nificantly between the control and challenge
studies. The retained hepatic uptake ratio was also
significantly lower in the UDCA pretreatment
cases (p=0.001). When the UDCA pretreatment
was applied, the time duration until visualization
of the GB was shortened, and the maximum
activity of the GB became more intense (Fig. 3).
DISCUSSION
The results of the volunteer study indicate that
the UDCA accelerates the hepatocyte excretion of
the
99mTc DISIDA as well as the bile into the bili-
ary tree, and
99mTc DISIDA results in an earlier
and more intense visualization of the GB in
hepatobiliary scintigraphy.
Fig. 1. Hepatobiliary scintigraphies of a volunteer un-
treated with UDCA (A) and pretreated with UDCA (B).
After pretreatment with UDCA, the GB (arrow) is visu-
alized first, then the intestine.
Table 1. Comparison of the Quantitative Results of Several Factors Analyzed from the Scintigraphic Findings
Control UDCA p-value
TGB 14.2 ± 6.6 min 9.1 ± 2.8 min 0.037*
TCBD 9.9 ± 2.3 min 11.9 ± 7.0 min 0.407
Tintestine 13.7 ± 6.1 min 20.4 ± 12.4 min 0.172
TmaxLiver 13.8 ± 7.4 min 12.5 ± 7.8 min 0.620
AmaxGB 83.8 ± 38.4 132.3 ± 59.8 0.043*
AmaxLiver 3.7 ± 3.3 3.5 ± 0.9 0.861
ERliver 80.3 ± 3.5% 82.7 ± 3.0% 0.001*
Data were expressed as mean±SD, and a p<0.05 was considered statistically significant.
TGB, TCBD, and Tintestine: times until observation in the GB, CBD and intestine; TmaxLiver: time until maximal activity of the liver;
AmaxGB and AmaxLiver: maximal activities of the GB and liver over one hour; ERliver: excretory ratio of liver over one hour
Fig. 2. Comparison of the time to visualization of the GB.
The observation times of the GB converged without
significant individual differences in eight cases of the
UDCA pretreated hepatobiliary scintigraphies.
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As mentioned above, morphine augmentation
and CCK pretreatment have been used for phar-
macological interventions applied to hepatobiliary
scintigraphy. However, the difficulty in accessing
these pharmaceutical agents limits their clinical
use. UDCA has been used in patients with chole-
stasis and in people with indigestion, and the
dose (200 mg) of the UDCA used in this study is
considered relatively low. Therefore, if UDCA
pretreatment for hepatobiliary scintigraphy were
to have the possibility of shortening the total
study time and enhancing the diagnostic accuracy,
and if UDCA were thought to be safe and to have
little limitations on its use, then this protocol
would be widely used. Therefore, the results of
our study give important and objective informa-
tion for providing a new pharmacological inter-
vention. Recently, although the interventional pro-
tocol (repeated oral administration every 12 h for
48-72 h) of UDCA was different, there was a
report that pretreatment with UDCA significantly
improves the specificity of hepatobiliary scinti-
graphy in ruling out extrahepatic biliary atresia as
a cause of prolonged neonatal jaundice.
8
There are many indications for hepatobiliary
scintigraphy. Practically, however, hepatobiliary
scintigraphy has been mainly used to diagnose
acute cholecystitis in adults and to rule out biliary
atresia in neonates. Due to the characteristics of
the patients examined in hepatobiliary studies,
there is difficulty in investigating comparisons
with other protocols in the cases of patients with
suspected acute cholecystitis. In our department,
we are using the method of UDCA pretreatment
when performing hepatobiliary scintigraphy. This
intervention helps us complete the clinical study
earlier, and minimizes inconvenience for the
patient.
In summary, UDCA-pretreated
99mTc DISIDA
scintigraphy showed a unified tendency of the
excretory pattern, in which the liver, GB, and
intestine were observed sequentially. The UDCA
allowed the DISIDA to enter the GB easily, and
the GB was filled with a greater amount of
DISIDA as compared with the control study
(Table 1). Although a large-scale clinical appli-
cation is needed for a precise conclusion, one dose
(200 mg) of UDCA pretreatment for hepatobiliary
scintigraphy is considered to increase excretion of
99mTc DISIDA from liver to GB, and to shorten the
total imaging time for evaluating functional
obstructions of the cystic duct. These results might
improve the specificity of hepatobiliary scinti-
graphy in patients with suspected acute cho-
lecystitis.
ACKNOWLEDGMENT
Authors thanks for the efforts of Chun Ho Lee,
Jong Cheol Kim, and Nam Ju Lee, the tech-
nologists of department of nuclear medicine, in
Wonkwang University Hospital for technical as-
sistance to acquire gamma camera images.
REFERENCES
1. Shea JA, Berlin JA, Escarce JJ, Clarke JR, Kinosian BP,
Cabana MD, et al. Revised estimates of diagnostic test
sensitivity and specificity in suspected biliary tract
disease. Arch Intern Med 1994;154:2573-81.
2. Choy D, Shi EC, McLean RG, Hoschl R, Murray IP,
Ham JM. Cholescintigraphy in acute cholecystitis: use
of intravenous morphine. Radiology 1984;151:203-7.
3. Fink-Bennett D. Augmented cholescintigraphy: its role
in detecting acute and chronic disorders of the hepato-
biliary tree. Semin Nucl Med 1991;21:128-39.
4. Angulo P. Use of ursodeoxycholic acid in patients with
liver disease. Curr Gastroenterol Rep 2002;4:37-44.
5. Van de Meeberg PC, van Erpecum KJ, van Berge-
Henegouwen GP. Therapy with ursodeoxycholic acid
in cholestatic liver disease. Scand J Gastroenterol Suppl
1993;200:15-20.
6. Arrese M, Pizarro M, Solis N, Koenig C, Accatino L.
Enhanced biliary excretion of canalicular membrane
Fig. 3. Hepatobiliary scintigraphies from a volunteer with
untreated UDCA (A) and pretreated UDCA (B). After
pretreatment with UDCA, the maximum activity of the GB
is more intense than that in the control study.
A BHwan-Jeong Jeong and Chang-Guhn Kim
Yonsei Med J Vol. 46, No. 3, 2005
enzymes in ethynylestradiol-induced cholestasis. Effects
of ursodeoxycholic acid administration. Biochem Phar-
macol 1995;50:1223-32.
7. Poupon R, Poupon RE. Ursodeoxycholic acid therapy
of chronic cholestatic conditions in adults and children.
Pharmacol Ther 1995;66:1-15.
8. Poddar U, Bhattacharya A, Thapa BR, Mittal BR, Singh
K. Ursodeoxycholic acid-augmented hepatobiliary scin-
tigraphy in the evaluation of neonatal jaundice. J Nucl
Med 2004;45:1488-92.